

# Amgen Pioneer Dr George Morstyn Joins Actinogen Board

- Former Amgen Executive, Dr George Morstyn joins Actinogen Medical as Non-Executive Director
- Dr Morstyn will work with Actinogen's high calibre team to guide and optimise the development of Xanamem™ for Alzheimer's disease and other neurodegenerative conditions.
- Dr Morstyn brings extensive drug development experience to the role, with many new products receiving marketing approval and having been launched during his tenure at US biotech giant, Amgen

**Sydney, 1 December 2017: Actinogen Medical (ASX: ACW)** today announces that pioneering drug developer and former Amgen Inc. Executive, Dr George Morstyn, has now joined the Actinogen Medical Board as a Non-Executive Director.

This follows the Company's announcement on 2 November 2017 that Dr Morstyn would join the Board effective 1 December 2017.


"We are delighted to welcome George to the Board and to have a global drug development pioneer of his calibre in our Company. His appointment is testament to the potential of our drug, Xanamem and the magnitude of the unmet medical need in Alzheimer's disease," said Dr Bill Ketelbey, CEO of Actinogen Medical.

#### **ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

@BillKetelbey



Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the  $11\beta$ -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most

affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

#### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.